3-methyl-2-phenyl-pyrazolo[1,5-a]pyridine | 17408-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-methyl-2-phenyl-pyrazolo[1,5-a]pyridine
• 英文别名: 3-methyl-2-phenyl-pyrazolo[1,5-a]pyridine；2-Phenyl-3-methylpyrazolo-<1,5-a>-pyridin；2-Phenyl-3-methyl-pyrazolo<1,5-a>pyridin；3-Methyl-2-phenylpyrazolo[1,5-a]pyridine
• CAS: 17408-32-1
• 化学式: C₁₄H₁₂N₂
• 分子量: 208.263
• InChiKey: ORZSSAOPOAUMTL-UHFFFAOYSA-N

物化性质

• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  苯,(2-硝基-1-丙烯基)-,(E)- 、 1-氨基吡啶碘 在 氧气 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 24.0h， 以83%的产率得到3-methyl-2-phenyl-pyrazolo[1,5-a]pyridine
  参考文献：
  名称：

  Substrate selective synthesis of pyrazolo[1,5-a]pyridines through [3 + 2] cycloaddition of N-aminopyridines and β-nitro styrenes

  摘要：

  通过[3 + 2]环加成法合成2或3-(杂)芳基吡唑并[1,5-a]吡啶，方法是使用N-氨基吡啶与β-硝基苯乙烯进行环加成，然后在无金属和温和条件下进行原位去硝化。

  DOI：

  10.1039/c5ra06707c

文献信息

• HETEROARYLS AND USES THEREOF
  申请人：MILLENNIUM PHARMACEUTICALS, INC.

  公开号：US20130165464A1

  公开（公告）日：2013-06-27

  This invention provides compounds of formula IB: and also provides compounds of formulas ID, IIB, VB, and IIC: wherein HY, R 1 , R 2 , G 5 , G 6 , G 7 , G 8 , and G 9 are as described in the specification. The compounds are inhibitors of VPS34 and/or PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  这项发明提供了以下式IB的化合物： 并且还提供了以下式ID、IIB、VB和IIC的化合物： 其中HY、R1、R2、G5、G6、G7、G8和G9如规范中所述。这些化合物是VPS34和/或PI3K的抑制剂，因此对于治疗增殖性、炎症性或心血管疾病是有用的。
• ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT
  申请人：NIHON NOHYAKU CO., LTD.

  公开号：US20160213640A1

  公开（公告）日：2016-07-28

  The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and an anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein R 1 is a hydrogen atom, an alkyl group and the like, R 2 , R 3 , and R 4 are the same or different and each is a hydrogen atom, an alkyl group and the like, R 5 and R 6 are the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Ar 1 is a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is —O—, —S—, —SO 2 —, or —N(R 7 )— wherein R 7 is a hydrogen atom, a (C 1 -C 6 )alkyl group and the like, or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有高安全性和优越抗癌活性的抗癌剂，以及一种含有氨基乙腈化合物作为活性成分的抗癌剂，所述氨基乙腈化合物由以下式(I)表示：其中R1为氢原子、烷基等，R2、R3和R4相同或不同，每个为氢原子、烷基等，R5和R6相同或不同，每个为氢原子、卤原子等，m为0或1，R为卤原子、氰基、硝基、苯基（可选择地由烷基取代）等，烷基等，Ar1为苯基、萘基、吡啶基、吡唑基等，每个均可选择地由卤原子、氰基、硝基、烷基等取代，W为—O—、—S—、—SO2—或—N(R7)—，其中R7为氢原子、(C1-C6)烷基等，或其药理学上可接受的盐。
• [EN] ANTI CANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT<br/>[FR] AGENT ANTICANCÉREUX COMPRENANT UN COMPOSÉ D'AMINOACÉTONITRILE EN TANT QUE PRINCIPE ACTIF
  申请人：NIHON NOHYAKU CO LTD

  公开号：WO2016137010A1

  公开（公告）日：2016-09-01

  The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein R1 is a hydrogen atom, an alkyl group and the like, R2, R3, and R4 are the same or different and each is a hydrogen atom, an alkyl group and the like, R5 and R6 are the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Ar1 is a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is -O-, -S-, -SO2-, or -N(R7)- wherein R7 is a hydrogen atom, a (C1-C6) alkyl group and the like, or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有高安全性和优越抗癌活性的抗癌药物，该抗癌药物含有作为活性成分的氨基乙腈化合物，其化学式表示为（I），其中R1是氢原子、烷基等，R2、R3和R4相同或不同，每个是氢原子、烷基等，R5和R6相同或不同，每个是氢原子、卤原子等，m为0或1，R是卤原子、氰基、硝基、苯基（可选择地由烷基取代）等，Ar1是苯基、萘基、吡啶基、吡唑基等，每个基可选择地由卤原子、氰基、硝基、烷基等取代，W是-O-、-S-、-SO2-或-N(R7)-，其中R7是氢原子、（C1-C6）烷基等，或其药理学上可接受的盐。
• Anticancer agent comprising aminoacetonitrile compound as active ingredient
  申请人：PITNEY PHARMACEUTICALS PTY LIMITED

  公开号：US10292960B2

  公开（公告）日：2019-05-21

  The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and an anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein R1 is a hydrogen atom, an alkyl group and the like, R2, R3, and R4 are the same or different and each is a hydrogen atom, an alkyl group and the like, R5 and R6 are the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Ar1 is a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is —O—, —S—, —SO2—, or —N(R7)— wherein R7 is a hydrogen atom, a (C1-C6) alkyl group and the like, or a pharmacologically acceptable salt thereof.

  本发明涉及一种安全性高、抗癌活性强的抗癌剂，以及一种含有由式（I）表示的氨基乙腈化合物作为活性成分的抗癌剂。 其中 R1 是氢原子、烷基等，R2、R3 和 R4 相同或不同且各自是氢原子、烷基等，R5 和 R6 相同或不同且各自是氢原子、卤素原子等，m 是 0 或 1，R 是卤素原子、氰基、硝基、任选被烷基取代的苯基等、Ar1 是苯基、萘基、吡啶基、吡唑基或类似基团，其中每个基团可选被卤素原子、氰基、硝基、烷基或类似基团取代；W 是-O-、-S-、-SO2-或-N(R7)-，其中 R7 是氢原子、（C1-C6）烷基或类似基团，或其药理学上可接受的盐。
• Anti-cancer agent comprising aminoacetonitrile compound as active ingredient
  申请人：Pitney Pharmaceuticals Pty Limited

  公开号：US10391076B2

  公开（公告）日：2019-08-27

  The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein R1 is a hydrogen atom, an alkyl group and the like, R2, R3, and R4 are the same or different and each is a hydrogen atom, an alkyl group and the like, R5 and R6 are the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Ar1 is a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is —O—, —S—, —SO2—, or —N(R7)— wherein R7 is a hydrogen atom, a (C1-C6)alkyl group and the like, or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有高度安全性和优异抗癌活性的抗癌剂，以及含有由式(I)表示的氨基乙腈化合物作为活性成分的抗癌剂，其中R1是氢原子、烷基等，R2、R3和R4相同或不同，各自是氢原子、烷基等，R5和R6相同或不同，各自是氢原子、卤素原子等，m是0或1，R是卤素原子、氰基、硝基、任选被烷基等取代的苯基、烷基等，Ar1是苯基、萘基、烷基等，R2、R3和R4相同或不同，各自是氢原子、烷基等，R5和R6相同或不同，各自是氢原子、卤素原子等，m是0或1，R是卤素原子、氰基、硝基、任选被烷基等取代的苯基、烷基等、氰基、硝基、任选被烷基等取代的苯基、烷基等，Ar1 是苯基、萘基、吡啶基、吡唑基等，其中每个基团任选被卤素原子取代、W为-O-、-S-、-SO2-或-N(R7)-，其中 R7 为氢原子、(C1-C6)烷基等，或其药理上可接受的盐。